Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 9/20 | 0.63 |
| ▸ | WNT3A | P56704 | 9/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CTSD | P07339 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30609633 | 1.00 | CTNNB1 (0.63) | CTNNB1WNT3ANPC1HDAC8HDAC1 | |
| SCHEMBL15979734 | 0.93 | CTNNB1 (0.71) | CTNNB1WNT3ANPC1HDAC8HDAC1 | |
| SCHEMBL6626765 | 0.91 | HDAC8 (0.66) | CTNNB1WNT3ANPC1HDAC8HDAC1 | |
| SCHEMBL27688476 | 0.90 | HDAC8 (0.68) | CTNNB1WNT3ANPC1HDAC8HDAC1 | |
| SCHEMBL15979736 | 0.88 | NPC1 (0.76) | CTNNB1WNT3ANPC1HDAC8HDAC1 | |
| SCHEMBL28289027 | 0.87 | NPC1 (0.60) | CTNNB1WNT3ANPC1HDAC8HDAC1 | |
| SCHEMBL18725727 | 0.85 | KMT2A (0.52) | CTNNB1WNT3ANPC1LMNAHTT | |
| SCHEMBL5189580 | 0.84 | CTNNB1 (0.61) | CTNNB1WNT3ANPC1HDAC8HDAC1 | |
| SCHEMBL31686110 | 0.84 | CTNNB1 (0.66) | CTNNB1WNT3ANPC1HDAC8HDAC1 | |
| SCHEMBL26644901 | 0.84 | CTNNB1 (0.66) | CTNNB1WNT3ANPC1HDAC8HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| EP-1745004-B1 | ARYL KETONE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2016-05-18 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-9035085-B2 | Aryl ketone compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | claimed |
| US-20080167217-A1 | aryl ketone compounds and compositions containing them which facilitate the delivery of active agents. The aryl ketone compounds have the formula** Image-1or a salt thereof, where n=1 to 9, and R1 to R5 are independently hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, C2 to C4 alkenyl, halogen, hydroxyl, | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-07-10 | — | — | US | claimed |
| CN-1029932-C | Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers | BIORESEARCH INC (US) | 1995-10-11 | — | — | CN | claimed |
| CN-1060770-A | The sweetness inhibitor that contains substantially tasteless is as bitter inhibitor or contain the absorbed thing of the bitter inhibitor of substantially tasteless as sweetness inhibitor | BIORESEARCH INC (US) | 1992-05-06 | — | — | CN | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| US-9777015-B2 | Useful thiophene derivatives in the treatment of diabetes | METABRAIN RESEARCH (FR) | 2017-10-03 | — | — | US | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-1745004-B1 | ARYL KETONE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2016-05-18 | — | — | EP | disclosed |
| CN-1029932-C | Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers | BIORESEARCH INC (US) | 1995-10-11 | — | — | CN | disclosed |
| CN-1060770-A | The sweetness inhibitor that contains substantially tasteless is as bitter inhibitor or contain the absorbed thing of the bitter inhibitor of substantially tasteless as sweetness inhibitor | BIORESEARCH INC (US) | 1992-05-06 | — | — | CN | disclosed |
| US-5063230-A | Substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their use as pharmacological agents | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-11-05 | — | — | US | disclosed |
| WO-1990006113-A1 | SUBSTITUTED SATURATED AND UNSATURATED INDOLE QUINOLINE AND BENZAZEPINE CARBOXAMIDES AND THEIR USE AS PHARMACOLOGICAL AGENTS | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1990-06-14 | — | — | WO | disclosed |
| US-4920219-A | Substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their use as pharmacological agents | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| EP-0156317-A2 | Foodstuffs containing sweetness inhibiting agents and process for inhibiting the sweetness perception of a foodstuff | GENERAL FOODS CORPORATION (US) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | CTNNB1 4034/4885WNT3A 3198/4885NPC1 1607/4885 |
| US-20080167217-A1 | aryl ketone compounds and compositions containing them which facilitate the delivery of active agents. The aryl ketone compounds have the formula** Image-1or a salt thereof, where n=1 to 9, and R1 to R5 are independently hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, C2 to C4 alkenyl, halogen, hydroxyl, | AKR1C3, AKR1C1, AKR1A1 | CTNNB1 2326/4885WNT3A 3475/4885NPC1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.